Regeneron Pharmaceuticals (REGN) has disclosed a new risk, in the Natural and Human Disruptions category.
Regeneron Pharmaceuticals has faced significant challenges due to the COVID-19 pandemic, and future public health crises pose a similar threat. The company’s economic stability, supply chain, research efforts, and workforce could be severely disrupted by such events. This vulnerability could lead to a material adverse impact on Regeneron’s business operations and financial health. Moreover, any public health emergency could exacerbate existing risks, amplifying the potential negative effects on the company’s outlook and performance.
The average REGN stock price target is $1,027.24, implying 9.71% upside potential.
To learn more about Regeneron Pharmaceuticals’ risk factors, click here.
